


FORM PTO-1449 (modified)
To: U.S. Department of Commerce
Patent and Trademark Office



**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket No.

Client Ref.

056291-5184

Applicant: Anderson J. Ryan

Appln. No.: 10/511,744

Filing Date: October 18, 2004

Examiner: Unassigned

Group Art Unit: 1646

Date: July 28, 2005

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	6,423,753 B1	07/2002	Dougherty			
1.	5,770,599	06/1998	Gibson			
2.	5,616,582	04/1997	Barker			
3.	5,457,105	10/1995	Barker			
4.	2003-0144298 A1	07/2003	Curwen et al.			
5.	2003-0166617 A1	09/2003	Davis et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclosed	No
6.	96/33980	031/1996	WO	Gibson (equivalent to US 6,770,599)				
7.	99/02166	01/1999	WO	Dougherty (equivalent to US 6,423,753)				
8.	00/48591	08/2000	WO	Davis et al.				
9.	01/32651 A1	05/2001	WO	Hennequin et al.				
10.	01/74360 A1	10/2001	WO	Curwen et al.				
11.	01/74368 A1	10/2001	WO	Davis et al.				
12.	02/056692 A1	07/2002	WO	Lee et al.				

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

13.	Baker et al., "Blockade of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for Therapy of Metastatic Human Pancreatic Cancer", Cancer Research, 62, April 2002, pp. 1996-2003			
14.	Blakey et al., "Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models", Clinical Cancer Research, vol. 8, 2002, pp. 1974-1983			
15.	Bruns et al., "Vascular-targeting activity of ZD6126 against primary pancreatic tumour growth and lymph node metastasis following orthotopic tumour cell injection in a nude mouse model", European Journal of Cancer, vol. 38, Suppl. 7, November 2, p. 40			
16.	Chaplin et al., "The Development of Combretastatin A4 Phosphate as a Vascular Targeting Agent", Int. J. Radiation Oncology Biol. Phys. vol. 54, no. 5, 2002, pp. 1491-1496			
17.	Ciadiello et al., "Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor", Clinical Cancer Research, vol. 6, May 2000, pp. 2053-2063			

Examiner


Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Crossed out documents previously

Consided and acknowledged

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
Patent and Trademark Office



Attorney Docket No.

Client Ref.

056291-5184

Applicant: Anderson J. Ryan

Appln. No.: 10/511,744

Filing Date: October 18, 2004

Examiner: Unassigned

Group Art Unit: 1646

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Date: July 28, 2005

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	6,906,048	06/2005	Davis et al.			

FOREIGN PATENT DOCUMENTS

Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	English Abstract	Translation Readily Available
				Enclosed No	Enclosed No

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

18.	Giardiello et al., "Antiangiogenic and Antitumor Activity of Anti-Epidermal Growth Factor Receptor C225 Monoclonal Antibody in Combination with Vascular Endothelial Growth Factor Antisense Oligonucleotide of Human GEO Colon Cancer Cells", Clinical Cancer Research, vol. 6, September 2000, pp. 3739-3747				
19.	Giardiello et al., "A Novel Approach in the Treatment of Cancer: Targeting the Epidermal Growth Factor Receptor", Clinical Cancer Research, vol. 7, no. 10, October 2001, pp. 2958-2970				
20.	Davis et al., "ZD6126: A Novel Vascular-targeting Agent That Causes Selective Destruction of Tumor Vasculature", Cancer Research, 62, December 2002, pp. 7247-7253				
21.	Grosios et al., "Combination Chemotherapy with Combretastatin A-4 Phosphate and 5-Fluorouracil in an Experimental Murine Colon Adenocarcinoma", Anticancer Research, 20, 2000, pp. 229-234				
22.	Horsman et al., "Combretastatins Novel Vascular Targeting Drugs for Improving the Anti-Cancer Therapy", Adv. Exp. Med. Biol. 2000, 476, pp. 311-323				
23.	Huang et al., "Modulation of Radiation Response and Tumor-induced Angiogenesis after Epidermal Growth Factor Receptor Inhibition by ZD1839 (Iressa)", Cancer Research, 62, August 2002, pp. 4300-4306				


Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*Crossed-out documents previously
considered and acknowledged*

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
Patent and Trademark Office



Attorney Docket No.	Client Ref.
056291-5184	
Applicant: Anderson J. Ryan	
Appln. No.: 10/511,744	
Filing Date: October 18, 2004	
Examiner: Unassigned	Group Art Unit: 1646

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Date: July 28, 2005

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	English Abstract		Translation Readily Available	
				Enclosed	No	Enclosed	No

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

24.	Li et al., "Preclinical Evaluations of Therapies Combining the Vascular Targeting Agent Combretastatin A-4 Disodium Phosphate and Conventional Anticancer Therapies in the Treatment of Kaposi's Sarcoma", Acta Oncologica, 41, 2002, pp. 91-97			
25.	Raben et al., "ZD1839, a Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Alone and in Combination With Radiation and Chemotherapy as a New Therapeutic Strategy in Non-Small Cell Lung Cancer", Seminars in Oncology, vol. 29, no. 1, Suppl 4, February 2000, pp. 37-46 2002			
26.	Siemann et al., "Vascular Targeting Agents Enhance Chemotherapeutic Agent Activities in Solid Tumor Therapy", Int. J. Cancer, 99, 2002, pp. 1-6			
27.	Siemann et al., "Enhancement of Radiation Therapy by the Novel Vascular Targeting Agent ZD6126", Int. J. Radiation Oncology Bio. Phys., vol. 53, no. 1, 2002, pp. 164-171			
28.	Sirotnak et al., "Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced by Coadministration of ZD1839 (Iressa), and Inhibitor of EGFR Tyrosine Kinase", Clinical Cancer Research, vol. 6, December 2000, pp. 4885-4892			
29.	Thorpe et al., The First International Conference on Vascular Targeting: Meeting Overview", Cancer Research, 63, March 2003, pp. 1144-1147			
30.	Vitoria-Petit et al., "Acquired Resistance to the Antitumor Effect of Epidermal Growth Factor Receptor-blocking Antibodies in Vivo: A Role for Altered Tumor Angiogenesis", Cancer Research, 61, July 2001, pp. 5090-5101			

Examiner _____ Date Considered: _____

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*Crossed out documents previously
considered and acknowledged*